Study wrapper · #935

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.

Hitaka K, Sugawara T, Matsumoto M, et al. International journal of obesity (2005). 2026.

DOI: 10.1038/s41366-026-02025-2PubMed: 41733725

Weak / noneAnimal (in vivo)Mentions: RetatrutideMentions: TirzepatideMentions: Semaglutide

Editor's note

This animal study directly compares three tracked peptides in MC4R-knockout mice, a model of severe genetic obesity, so all three are central subjects. All reduced body weight and improved insulin, lipid, and liver markers, with tirzepatide showing the greatest effect. Findings are preclinical, and the authors note the model aligns with clinical observations.

Plain-language abstract

In mice lacking the MC4R gene, semaglutide, tirzepatide, and retatrutide all reduced body weight and improved metabolic markers, with tirzepatide producing the largest weight reduction.

Mixed